

CHIRAL SYNTHESIS OF THROMBOXANE B₂ INTERMEDIATES

Oscar Hernandez

Environmental Biology and Chemistry Branch
and Laboratory of Pharmacology







National Institute of Environmental Health Sciences

Research Triangle Park, North Carolina 27709 USA

(Received in USA 26 September 1977; received in UK for publication 21 November 1977)

The prostaglandins endoperoxides PGG₂ and PGH₂ are metabolized in human platelets to a new group of biologically active compounds called the thromboxanes¹. Thromboxane A₂ (TXA₂) has been suggested to play a critical role in platelet aggregation. TXA₂ is unstable in aqueous solution and it is rapidly hydrolyzed to thromboxane B₂ (TXB₂)².

The lack of availability of these compounds for our program on the effects of environmental agents in prostaglandin biosynthesis³ was incentive for designing an efficient synthesis of thromboxanes. A major problem in working with racemic materials is the loss usually associated with the optical resolution of the desired intermediate. The use of carbohydrates as optically pure precursors has been demonstrated by Fraser-Reid who envisaged the advantages implicit in this approach⁴. Our initial goal was to prepare an intermediate such as 5 from which we anticipated TXB₂ could be synthesized by following the methodology perfected by Corey for the synthesis of prostaglandins⁵. The publication of a series of papers on the synthesis of TXB₂ by three groups at the Upjohn Company confirmed our expectation in that in two of those syntheses, intermediates similar to 5 were successfully transformed to TXB₂⁶. In this communication we describe a stereoselective, chiral synthesis of compound 5 starting with commercially available α -methylglucoside (1a)⁷. The strategy described features the sequential activation of the hydroxyl groups of glucose, culminating with the introduction of the acetic acid side chain at C-4 (glucose numbering) in a stereochemically predictable manner. After this work was completed, E.J. Corey and coworkers¹⁸ reported a synthesis of TXB₂ similar to the one described here. Reaction of methyl- α -D-glucopyranoside (1a) with triphenylmethyl chloride (triethylamine, dimethylformamide, catalytic amount of 4-dimethylaminopyridine)⁷ gave the tritylether 1b (85%)⁸, mp 154.5-155.5° (lit.⁹ 151-152°); m/e 436 (M⁺)¹⁰, 404 (M⁺-CH₃OH), 359 (M⁺-C₆H₅). Selective activation of the hydroxyl group at C-2 was achieved by formation of the di-*n*-butylstannylene derivative (di-*n*-butyltin oxide, refluxing methanol)¹¹, which was subsequently transformed^{11b} (benzoyl chloride, triethylamine, tetrahydrofuran) to 1c (85%), mp 93-95°, [α]_D + 120° (c, 2), m/e 540 (M⁺), 508 (M⁺-32). Reaction of 1c with methanesulfonyl chloride (triethylamine, dichloromethane) gave the dimesylate 1d (80%), mp 174.5-176.5° (lit.¹² 169-170°), m/e 696 (M⁺), 619 (M⁺-C₆H₅). Treatment of 1d with zinc-copper couple and potassium iodide in refluxing dimethylformamide¹³ produced a mixture of 2a and 2b. Transesterification (sodium



methoxide, dichloromethane-methanol) afforded pure 2b (75%), mp 123-125° (lit¹² 122-123°); m/e 502 (M⁺), 460 (M⁺-CH₃OH). The allylic alcohol 2b when subjected to the conditions of the orthoester Claisen rearrangement¹⁴ (trimethylorthoacetate, propionic acid, refluxing xylene) was transformed to the ester 3 (65%), mp 78-80°; [α]_D + 90° (c, 1.1); m/e 458 (M⁺), 426 (M-CH₃OH). Alkaline hydrolysis (sodium hydroxide, aqueous tetrahydrofuran) of 3 followed by reaction with potassium iodide-iodine in 0.5 M sodium bicarbonate¹⁵ gave the iodolactone 4 (90%) mp 221-223°; [α]_D + 42° (c, 0.8), m/e 570 (M⁺), 493 (M⁺-C₆H₅). Reduction of 4 with tri-n-butyltin hydride^{15,16} (nBu₃SnCl, NaBH₄, 50% ethanol-tetrahydrofuran) afforded the highly crystalline lactone 5a (95%), mp 241-243°; [α]_D + 78° (c, 0.5); m/e 444 (M⁺), 412 (M⁺-CH₃OH). Removal of the trityl group (hydrogen chloride, dichloromethane) yielded the desired intermediate hydroxylactone 5b (85%), mp 102-103°; [α]_D + 85 (c, 0.5); m/e 202 (M⁺), 170 (M⁺-CH₃OH). The infrared and nuclear magnetic resonance spectra of 5b were identical to those of an authentic sample¹⁷. The subsequent steps leading to TXB₂ are described in the literature^{6a,b;18}.

The preparation of compound 5b represents a solution to the main stereochemical problem in TXB₂ synthesis, namely development of the three contiguous chiral centers with strict stereochemical control. In summary, the synthetic sequence described provides a short and efficient route to optically pure thromboxanes.

References and Notes

1. M. Hamberg, J. Svensson, and B. Samuelsson, Proc. Nat. Acad. Sci. USA, 72, 2994 (1975).
2. B. Samuelsson and R. Paoletti, "Advances in Prostaglandin and Thromboxane Research", Raven Press, New York, 1976.
3. D. G. Parkes and T. E. Eling, Biochem. J., 146, 549 (1975).
4. (a) R. C. Anderson and B. Fraser-Reid, J. Am. Chem. Soc., 97, 3870 (1975); (b) D. R. Hicks and B. Fraser-Reid, J.C.S. Chem. Comm., 869 (1976).
5. E. J. Corey, S. M. Albonico, V. Koelliker, T. K. Schaaf, and R. K. Varma, J. Am. Chem. Soc., 93, 1491 (1971), and references cited therein.
6. (a) N. A. Nelson and R. W. Jackson, Tetrahedron Lett., 3275 (1976); (b) R. C. Kelly, I. Schletter, and S. J. Stein, *ibid.*, 3279 (1976); (c) W. P. Schneider and R. A. Morge, *ibid.*, 3283 (1976).
7. O. Hernandez and S. K. Chaudhary, in preparation.
8. All compounds described herein had infrared and proton magnetic resonance spectral data consistent with the assigned structures. No attempts were made to optimize the yields. Optical rotations were determined in chloroform solutions.
9. B. Helferich and J. Becker, Ann., 440, 1 (1924).
10. Chemical ionization mass spectrum using nitric oxide as reagent gas.
11. (a) D. Wagner, J. P. H. Verheyden, and J. G. Moffatt, J. Org. Chem., 39, 24 (1974); (b) R. M. Munavu and H. H. Szmant, *ibid.*, 41, 1832 (1976).
12. N. L. Holder and B. Fraser-Reid, Can. J. Chem., 51, 3357 (1973).

13. B. Fraser-Reid and B. Boctor, *Can. J. Chem.*, 47, 393 (1969).
14. W. S. Johnson, L. Wertheman, W. R. Bartlett, T. J. Brockson, T. Li, D. J. Faulkner, M. R. Petersen, *J. Am. Chem. Soc.*, 92, 741 (1974).
15. (a) H. O. House, S. G. Boots, and V. K. Jones, *J. Org. Chem.*, 30, 2519 (1965); (b) E. J. Corey, N. M. Weinshenker, T. K. Schaaf, and W. Huber, *J. Am. Chem. Soc.*, 91, 5675 (1969).
16. E. J. Corey and J. W. Suggs, *J. Org. Chem.*, 40, 2554 (1975).
17. Kindly provided by Dr. Norman A. Nelson from the Upjohn Company.
18. E. J. Corey, M. Shibasaki, and J. Knolle, *Tetrahedron Lett.*, 1625 (1977).